SCHEMBL4095307

SCHEMBL4095307

CC(=O)N1CCN(c2nc(-c3ccc(C(C)(C)C)cc3)nc3ccc(Cl)cc23)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
HDAC3 O15379 1/20 0.52
MTOR P42345 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
TP53 P04637 2/20 0.49
GBA1 P04062 7/20 0.48
AKT1 P31749 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.46
MGLL Q99685 1/20 0.45
USP2 O75604 2/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CLK1 P49759 1/20 0.44
GRIA1 P42261 1/20 0.43
TRPV1 Q8NER1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084671 0.92 HDAC3 (0.54) HDAC3MTORHDAC1HDAC2HDAC6
SCHEMBL13984098 0.90 MEN1 (0.53) MEN1RAB9AKMT2AHDAC3MTOR
SCHEMBL4085181 0.88 MEN1 (0.49) MEN1RAB9AKMT2AHDAC3MTOR
SCHEMBL4093185 0.86 MEN1 (0.51) MEN1RAB9AKMT2ATP53GBA1
SCHEMBL4092114 0.86 MEN1 (0.57) MEN1RAB9AKMT2AHDAC3MTOR
SCHEMBL4094693 0.85 MEN1 (0.72) MEN1RAB9AKMT2ATP53GBA1
SCHEMBL4755399 0.82 MEN1 (0.51) MEN1RAB9AKMT2AHDAC3MTOR
SCHEMBL4090401 0.81 GBA1 (0.64) MEN1RAB9AKMT2ATP53GBA1
SCHEMBL4097528 0.78 MEN1 (0.54) MEN1KMT2AHDAC3MTORHDAC1
SCHEMBL4095191 0.78 MAPT (0.62) MEN1KMT2AGBA1ABCG2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MEN1 718/4885RAB9A 640/4885KMT2A 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.